Clinical Trial Update: A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies [Phase 1]

View source ↗

Summary

An open-label Phase 1/II clinical trial evaluating CPI-613 (devimistat) in patients with advanced malignancies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• CPI-613 (devimistat)

Snippet

Sponsor: Cornerstone Pharmaceuticals | Conditions: Advanced Cancer, Metastatic Cancer | Phase 1 | Status: COMPLETED